Intellect Neurosciences (ILNS), ViroPharma (VPHM) Ink Licensing Agreement
Intellect Neurosciences Inc. today announced it has granted an exclusive license to ViroPharma Inc., in which the company will receive licensed patents and patent applications related to Intellect's orally administered, clinical stage drug candidate, OX1. ViroPharma plans to develop and commercialize OX1 to treat Friedreich's Ataxia, a disease that causes nervous system damages and affects movement, as well as for the treatment of diseases for which OX1 may qualify for orphan drug designation. "We are pleased to enter into a strategic relationship with ViroPharma, which has ample resources, drug development capabilities and orphan drug marketing expertise to accelerate the development…